MAPT and Alzheimer disease: Likewise, anti-inflammatory multiple sclerosis medication has shown promise in AD mouse models for reversing all Aβ, tau and microglia pathologies, and synaptic and cognitive dysfunction (Dionisio-Santos et al., 2021; Leßmann et al., 2023).